NATCO PHARMA LTD.
NSE : NATCOPHARMBSE : 524816ISIN
CODE : INE987B01026Industry : Pharmaceuticals & DrugsHouse
: Natco
BSE995.80-23.05 (-2.26 % )
PREV CLOSE (Rs.) 1018.85
OPEN PRICE (Rs.) 1017.85
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 56489
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE994.95 -21.1 (-2.08 % )
PREV CLOSE(Rs.) 1016.05
OPEN PRICE (Rs.) 1016.10
BID PRICE (QTY) 994.95 (20 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 487398
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 23-Apr-2024 | NATCO Pharma informs about disclosure | <div style="text-align: justify;">Further to its earlier intimation dated November 2, 2023 about the successful completion of United States Food and Drug Administration's (USFDA) inspection of the firm's compliance to Pharmacovigilance requirements with zero observations, NATCO Pharma has informed that the Company is in receipt of the Establishment Inspection Report (EIR) from USFDA concluding the inspection as Closed.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
| 18-Apr-2024 | NATCO Pharma informs about press release | <p style="text-align: justify;">NATCO Pharma has informed that it enclosed the Press Release and disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 09-Apr-2024 | Natco Pharma gets warning letter from USFDA for Telangana plant | <p style="text-align: justify;">Natco Pharma has received a warning letter from the US health regulator for its Telangana-based manufacturing plant. The US Food and Drug Administration (USFDA) had issued eight observations under Form 483 after inspecting the company's Kothur-based formulation facility. The inspection was conducted by USFDA from October 9 to October 18, 2023. The company does not believe that the warning letter will have an impact on supplies or the existing revenues from this facility. It may cause delay/withholding of pending product approvals from this site. </p><p style="text-align: justify;">The drug firm will respond to the letter within the stipulated timelines and work closely with the USFDA to address the concerns in a holistic and timely manner to ensure sustained compliance. A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations. </p><p style="text-align: justify;">Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.</p> |
| 09-Apr-2024 | NATCO Pharma informs about updates | <p style="text-align: justify;">NATCO Pharma has informed about update on USFDA inspection at Natco's manufacturing facility in Kothur, Telangana.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 09-Apr-2024 | Update On USFDA Inspection At Natco'S Manufacturing Facility In Kothur, Telangana | Update on USFDA inspection at NATCO''s Manufacturing facility in Kothur, Telangana |
| 06-Apr-2024 | NATCO Pharma informs about certificate | <p style="text-align: justify;">NATCO Pharma has informed that it enclosed Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations for the quarter ended March 31, 2024.<br></p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 05-Apr-2024 | Natco Pharma informs about details of loss of certificate | <div style="text-align: justify;">Natco Pharma has informed that the Company is in process of issuing duplicate share certificates in the following cases in lieu of the originals thereof, stated to have been lost by the respective shareholder: Roupali Agarwal; Folio No. 034149</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
| 26-Mar-2024 | Natco Pharma informs about closure of trading window | <div style="text-align: justify;">Natco Pharma has informed that the Trading Window for dealing in the securities of the Company would remain closed for the Directors, Designated Persons, their immediate relatives and all other connected persons covered in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time with effect from April 1, 2024 to till 48 hours after the declaration of the Financial Results of the Company for the quarter and year ending March 31, 2024. The date of the Board Meeting for declaration of the financial results of the Company for the quarter and year ending March 31, 2024 will be intimated in due course of time.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
| 02-Mar-2024 | Natco Pharma informs about analyst meet | <div>Natco Pharma has informed that it enclosed the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Also informed that the officials of the Company will be participating in the investor meeting as on 06.03.2024.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 01-Mar-2024 | Natco Pharma informs about details of loss of certificate | <div style="text-align: justify;">Natco Pharma has informed that they are in process of issuing duplicate share certificates in the following cases in lieu of the originals thereof, stated to have been lost by the respective shareholder: Venkataramana Murthy B M Susheela (Folio No. 031246)</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
